On December 10, 2014, the R&D Seminar on Chlorogenic Acid for Injection of Class I and II New Anti-tumor Drug convened by the Institute of Materia Medica, the Chinese Academy of Medical Sciences was held in Beijing. Attending Expert and Leader:
Academician SANG Guowei, National Institutes for Food and Drug Control
Academician ZHANG Baili, Tianjin University of Traditional Chinese Medicine
Chairman SONG Ruilin, China Pharmaceutical industry Research and Development Association
Minister ZHANG Yongxiang, Ministry of Science and Technology, Academy of Military Medical Sciences
President JI Jiafu, Beijing Cancer Hospital
SHAO Qingxiang, Zhejiang Academy of Medical Sciences
Director CHEN Shilin, Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences
Director SUN Xiaobo, Institute of Medicinal Plant Development
Vice Director YANG Shengwan, Information Center of National People's Congress of the People's Republic of China
MAO Junfeng, the General Office of the NPC Standing Committee
FENG Lan, China Pharmaceutical industry Research and Development Association
Prof. GONG Jifang, Beijing Cancer Hospital
The meeting was chaired by President JIANG Jiandong
Sichuan Jiuzhang Biological Science and Technology Co., Ltd. participated in this meeting as the pharmaceutical inventor. Mr. ZHANG Jie, Chairman and General Manager, Mr. HUANG Jun, Director of Technical R & D Department, made a summary report on the early-stage drug research and development and project progress.
ZHANG Jinlan, director of the Institute of Materia Medica summarized the preliminary application survey of chlorogenic acid.
CHEN Xiaoguang, vice-president and Party secretary of the Institute of Materia Medica, made an in-depth analysis on the internationally tumor therapy and immunotherapy for cancer at home and abroad. Then, Chen made an introduction for the anti-tumor mechanism of chlorogenic acid and compared it to the current therapy.
Experts attending the meeting held a discussion on Chlorogenic Acid Project and gave full affirmation to it.
